In a nutshell This study aimed to investigate the effectiveness and safety of bosutinib as a second line therapy for patients with chronic phase chronic myeloid leukemia (CML). This study concluded that bosutinib was effective and safe for these patients as a second line therapy. Some background Bosutinib (bosulif) is a tyrosine kinase inhibitor (TKI...
Read MoreLeukemia Posts on Medivizor
Bendamustine and rituximab as salvage treatment in chronic lymphocytic leukemia
In a nutshell This study aimed to measure the effectiveness of bendamustine and rituximab as salvage treatment in patients with chronic lymphocytic leukemia. This study concluded that bendamustine and rituximab are as effective as ibrutinib as salvage treatment in these patients. Some background The standard treatment for chronic lymphocytic...
Read MoreIs dasatinib effective with chemotherapy in the treatment of Philadelphia-chromosome postitive ALL?
In a nutshell This study examined the effect of dasatinib (Sprycel) in addition to intensive chemotherapy in the treatment of children and young adults with acute lymphoblastic leukemia (ALL). The study concluded that dasatinib with chemotherapy was a safe and effective way to treat ALL. Some background Acute lymphoblastic leukemia (ALL) is a...
Read MoreWhich treatment is better for mixed phenotype acute leukemia?
In a nutshell This study was a systematic review and meta-analysis (a review of all available and relevant research on a certain topic) on the best treatment of mixed phenotype acute leukemia (MPAL). Researchers determined that treatment used for acute lymphocytic leukemia (ALL) was linked with better outcomes than treatment for acute...
Read MoreCan tyrosine kinase inhibitors influence survival rates in chronic phase chronic myeloid leukemia?
In a nutshell This study aimed to investigate the side effects of tyrosine kinase inhibitors and their impact on outcomes in chronic-phase chronic myeloid leukemia patients. This study concluded that severe side effects from tyrosine kinase inhibitors can cause decreased survival rates in these patients. Some background Tyrosine kinase inhibitors...
Read MoreVenetoclax for chronic lymphocytic leukemia patients with 17p deletion
In a nutshell This study aimed to investigate the effectiveness of venetoclax in chronic lymphocytic leukemia patients with 17p deletion. This study concluded that venetoclax is effective in this group of patients. Some background 17p deletion chronic lymphocytic leukemia (17p del CLL) is a type of CLL that has a poor prognosis.Venetoclax...
Read MoreVenetoclax for chronic lymphocytic leukemia patients with 17p deletion
In a nutshell This study aimed to investigate the effectiveness of venetoclax in chronic lymphocytic leukemia patients with 17p deletion. This study concluded that venetoclax is effective in this group of patients. Some background 17p deletion chronic lymphocytic leukemia (17p del CLL) is a type of CLL that has a poor prognosis.Venetoclax...
Read MoreDoes ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...
Read MoreIs thiotepa-based reduced-intensity conditioning effective before cord blood stem cell transplantation?
In a nutshell This study examined the effectiveness of thiotepa-based RIC in leukemia and lymphoma patients undergoing stem cell transplantation. The authors concluded that this treatment improved outcomes compared to standard RIC. Some background Before undergoing stem cell transplantation, patients with lymphoma or leukemia must undergo conditioning...
Read MoreCan tyrosine kinase inhibitor treatment be stopped in CML patients with deep molecular response?
In a nutshell This study aimed to define the conditions necessary for stopping tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia. This study concluded that patients who maintain a deep molecular response have good molecular relapse-free survival and can be considered for treatment discontinuation. Some...
Read MoreLenalidomide and blood clots: low risk in CLL and NHL
In a nutshell This study examined the risk of venous thromboembolism (VTE, a blood clot that forms in the veins of the legs, arms, or groin) in patients treated with lenalidomide (Revlimid). The study concluded that the risk of VTE was low with lenalidomide treatment. Some background Lenalidomide is an effective treatment already used in multiple...
Read MorePreventing invasive fungal infections in acute leukemia patients
In a nutshell This study aimed to compare the effectiveness and tolerability of micafungin (Mycamine) and posaconazole (Noxafil) in acute leukemia patients undergoing chemotherapy. This study concluded that micafungin was effective as an antifungal prophylaxis in these patients. Some background Invasive fungal infections (IFIs) are...
Read More
